To hear about similar clinical trials, please enter your email below
Trial Title:
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
NCT ID:
NCT02203643
Condition:
MULTIPLE MYELOMA (MM)
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Dexamethasone
Cyclophosphamide
Lenalidomide
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Active, not recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Carfilzomib
Arm group label:
CCyd
Arm group label:
CRd
Arm group label:
CRd long treatment
Intervention type:
Drug
Intervention name:
Cyclophosphamide
Arm group label:
CCyd
Intervention type:
Drug
Intervention name:
Lenalidomide
Arm group label:
CRd
Arm group label:
CRd long treatment
Other name:
Revlimid
Intervention type:
Drug
Intervention name:
Dexamethasone
Arm group label:
CCyd
Arm group label:
CRd
Arm group label:
CRd long treatment
Summary:
This study will evaluate the safety and the efficacy of carfilzomib combined with
cyclophosphamide and dexamethasone (CCyd) or lenalidomide and dexamethasone (CRd)
followed by autologous transplantation ASCT or 12 cycles of carfilzomib combined with
dexamethasone and lenalidomide for patients eligible for ASCT with newly diagnosed
multiple myeloma. As a secondary endpoint this study will evaluate the best maintenance
treatment between lenalidomide and lenalidomide combined with carfilzomib.
Four hundred seventy-seven patients, males and females aged > 18 years, enrolled in
several sites, will take part in this study.
The duration of the study is approximately 5 years.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Age ≥ 18 years Newly diagnosed MM based on standard CRAB criteria (see appendix B).
Patient < 65 years eligible for ASCT. Patient has measurable disease according to IMWG
(International Myeloma Working Group) criteria.
Patient has given voluntary written informed consent. Patient agrees to use acceptable
methods for contraception. Patient has a Karnofsky performance status ≥ 60%
Pretreatment clinical laboratory values within 30 days of enrolment:
Platelet count ≥50 x 109/L (≥30 x 109 /L if myeloma involvement in the bone marrow is >
50%) Absolute neutrophil count (ANC) ≥ 1 x 109/L without the use of growth factors
Corrected serum calcium ≤14 mg/dL (3.5 mmol/L) Alanine transaminase (ALT): ≤ 3 x the
Upper Limit Normal (ULN) Total bilirubin: ≤ 2 x the ULN Calculated or measured creatinine
clearance: ≥ 30 mL/minute. LVEF≥40%. 2-D transthoracic echocardiogram (ECHO) is the
preferred method of evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO
is not available Life expectancy ≥ 3 months
Exclusion Criteria:
Previous treatment with anti-myeloma therapy (does not include radiotherapy,
bisphosphonates, or a single short course of steroid < to the equivalent of dexamethasone
40 mg/day for 4 days) Patients with non-secretory MM unless serum free-light chains are
present and the ratio is abnormal or a plasmocytoma with minimum largest diameters of > 2
cm Patients ineligible for autologous transplantation Pregnant or lactating females
Presence of:
Clinical active infectious hepatitis type A, B, C or HIV Acute active infection requiring
antibiotics or infiltrative pulmonary disease Myocardial infarction or unstable angina ≤
4 months or other clinically significant heart disease Peripheral neuropathy or
neuropathic pain grade 2 or higher, as defined by National Cancer Institute Common
Toxicity Criteria (NCI CTC) 4.0 Known history of allergy to Captisol ® (a cyclodextrin
derivative used to solubilize carfilzomib) Contraindication to any of the required drugs
or supportive treatments Invasive malignancy within the past 3 years Serious medical
condition, laboratory abnormality or psychiatric illness that prevented the subject from
the enrolment or place the subject at unacceptable risk.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
IRCCS--CROB --CROB di Rionero in di Rionero in Vulture
Address:
City:
Rionero in Vulture
Zip:
85028
Country:
Italy
Start date:
February 2015
Completion date:
October 2033
Lead sponsor:
Agency:
Mario Boccadoro
Agency class:
Other
Source:
University of Turin, Italy
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT02203643